Liver transplantation in Norway: Results after ten years and 114 transplantations;Levertransplantasjon i Norge: Resultater etter ti års aktivitet og 114 transplantasjoner

Tidsskrift for den Norske Laegeforening

Volumn 116, Issue 1, 1996, Pages 19-24

  Bjøro, Kristian ^a   Schrumpf, Erik ^a   Bergan, Anstein ^a   Flatmark, Audun ^a   Mathisen, Øystein ^a   Sødal, Gunnar ^a   Søreide, Odd ^a   Sanengen, Truls ^a   Innes, Robert ^a   Osnes, Svein ^a  

^a OSLO UNIVERSITY HOSPITAL   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

ADOLESCENT; ADULT; CHILD; GRAFT REJECTION; HOSPITAL ADMISSION; HUMAN; LIVER TRANSPLANTATION; MORTALITY; NORWAY; POSTOPERATIVE COMPLICATION; REVIEW; STANDARD; STATISTICS;

ADOLESCENT; ADULT; CHILD; GRAFT REJECTION; HUMANS; LIVER TRANSPLANTATION; NORWAY; POSTOPERATIVE COMPLICATIONS; WAITING LISTS;

EID: 0142193562     PISSN: 00292001     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (32)

1. National Institutes of Health Consensus Development Conference statement: Liver Transplantation - June 20-23, 1983. Hepatology 1983; 4 (suppl 1): 107-10.
2. Consensus conference on indication of liver transplantation. Hepatology 1994; 20 (suppl 1): 1-49.
3. Otte JB, de Ville J, Sokal E, Alberti D, Moulin D, Hemptinne B et al. Size reduction of the donor liver is a safe way to alleviate the shortage of size-matched organs in pediatric liver transplantation. Ann Surg 1990; 211: 146-57.
4. Norheim OF, Bjøro K, Schrumpf E, Søreide O. Er levertransplantasjon et underprioritert behandlingstilbud i Norge? Tidsskr Nor Lægeforen 1996; 116: 72-6.
5. European FK506 Multicentre Study Group. Randomised trial comparing tacrolimus (FK506) and cyclosporin in prevention of liver allograft rejection. Lancet 1994; 344: 423-8.
6. The U.S. Multicentre FK506 Liver Study group. A comparison of tacrolimus (FK506) and cyclosporin for immunsuppresion in liver transplantation. N Engl J Med 1994; 331: 1110-5.
7. Bismuth H, Castaing G. European Liver transplant Registry. Paris: Hopital Paul Brousse, 1993.
8. Keiding S, Ericzon BG, Eriksson S, Flatmark A, Höckerstedt K, Isoniemi H et al. Survival after liver transplantation of patients with primary biliary cirrhosis in the Nordic countries. Comparison with expected survival in another series of transplantations and in international trial of medical treatment. Scand J Gastroenterol 1990; 25: 11-8.
9. Christensen E, Altman DG, Neuberger J, de Stavola BL, Tygstrup N, Williams R. Updating prognosis in primary biliary cirrhosis using a time-dependent Cox-regression model. PBC1 and PBC2 trial groups. Gastroenterology 1993; 105: 1865-76.
10. Schrumpf E, Abdelnoor M, Fausa O, Elgjo K, Jensen E, Kolmannskog F. Risk factors in primary sclerosing cholangitis. J Hepatol 1994; 21: 1061-6.
11. Schrumpf E, Fausa O, Elgjo K, Kolmannskog F. Hepatobiliary complications of inflammatory bowel disease. Semin Liver Dis 1988; 8: 201-9.
12. Maddrey WC, Combes B. Therapeutic concepts for the management of idiopathic chronic hepatitis. Semin Liver Dis 1991; 11: 248-55.
13. Konig V, Hopf U, Neuhaus P, Bauditz J, Schmidt CA, Blumhardt G et al. Long-term follow-up of hepatitis B virus-infected recipients after orthotopic liver transplantation. Transplantation 1994; 58: 553-9.
14. van Thiel DH, Wright HI, Fagiuoh S. Liver transplantation for hepatitis B virus-related cirrhosis. Hepatology 1994; 20: 20-3.
15. Ascher NL, Lake JR, Emond J, Roberts J. Liver transplantation for hepatitis C virus-related cirrhosis. Hepatology 1994, 20: 24-7.
16. Chazouilleres O, Kim M, Combs C, Ferrel L, Bacchetti P, Roberts J et al. Quantitation of hepatitis C virus RNA in liver transplant recipients. Gastroenterology 1994; 106: 994-9.
17. Wright TL, Combs C, Kim M, Ferrel L, Bacchetti P, Ascher A et al. Interferon-alfa therapy for hepatitis C virus infection after liver transplantation. Hepatology 1994; 20: 773-9.
18. Pichlmayr R, Weimann A, Ringe B. Indications for liver transplantation in hepatobiliary malignancy. Hepatology 1994; 20: 33-40.
19. O'Grady JG, Polson RJ, Rolles K, Calne RY, Williams R. Liver transplantation for malignant disease: results in 93 consecutive patients Ann Surg 1988; 207: 373-9.
20. Osoria RW, Freise CE, Ascher NL, Roberts JP, Avery M, Lake JR. Orthotopic liver transplantation for end-stage alcoholic liver disease Transplant Proc 1993; 25: 1133-4.
21. Powell WJ jr., Klatskin G. Duration of survival in patients with Läennecs cirrhosis, influence of alcohol withdrawal, and possible effects of recent changes in general management of the disease. Am J Med 1968; 44: 406-20.
22. Lucey MR, Merion RM, Henley KS, Campbell DA, Turcotte JG, Nostrant TT et al. Selection for and outcome of liver transplantation in alcoholic liver disease. Gastroenterology 1992; 102: 1736-42.
23. Merion RM. Outcome of liver transplantation for alcohol-related liver disease. I: Lucey MR, Merion RM, Beresford TR, red. Liver transplantation and the alcoholic patient. Cambridge: Cambridge University Press, 1994: 80-95.
24. Höckerstedt K. Liver transplantation in alcoholic liver disease. Time for decision-making Transpl Int 1994; 7: 1-4.
25. Lindstedt S, Holme E, Lock EA, Hjalmarson O, Strandvik B. Treatment of hereditary tyrosinemia type 1 by inhibition of 4-hydroxyphenylpyruvate dioxygenase. Lancet 1992; 340: 813-7.
26. Howard ER. Biliary atresia: aetiology, management and complications. I: Howard ER, red Surgery of liver disease in infancy. London: Butterworth, 1991: 39-59.
27. Emblem R, Stake G, Monclair T. Progress in the treatment of biliary atresia: a plea for surgical intervention within the first two months of life in infants with persistent cholestasis. Acta Paediatt 1993, 82; 971-4.
28. Laurent J, Gauthier F, Bernard O, Hadchovel N, Odievre N, Valayer J et al. Long-term outcome after surgery for biliary atresia. Gastroenterology 1990; 99: 1795-7.
29. Otte JB, de Ville de Goyet J, Reding R, Hausleithner V, Sokal E, Chardot C et al. Sequential treatment of biliary atresia with Kasai portoenterostomy and liver transplantation: a review. Hepatology 1994; 20: 41-8.
30. Tygstrup N, Ranek L. Assessment of prognosis in fulminant hepatic failure. Semin Liver Dis 1986; 6: 129-37.
31. Boberg KM, Schrumpf E, Rogstad B, Berg KJ, Ganes T, Bergan A. Behandling av paracetamolforgiftning. Indikasjon for levertransplantasjon? Tidsskr Nor Lægeforen 1994; 114: 1199-203.
32. Höckerstedt K, Isoniemi H, Ericzon BG, Broome U, Friman S, Persson H et al. Is a 3-day waiting list appropriate for patients with acute liver failure? Transplant Proc 1994; 26: 1786-7